Epkinly

(Epcoritamab-bysp)

Epkinly

Drug updated on 11/27/2023

Dosage FormInjection (subcutaneous: 4 mg/0.8 mL in a single-dose vial; 48 mg/0.8 mL in a single-dose vial)
Drug ClassBispecific CD20-directed CD3 T-cell engager
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.